MIJ invests in biotechs developing the first-in-class or best-in-class pharmaceuticals, covering from the latest technologies such as regenerative medicine and gene therapy to new chemical entities and biotechs developing devices, digital health, and AI technologies that bring innovation to medical support to patients.
CareNet, Inc.（TSE 2150）
In addition to providing physicians and medical professionals with helpful information for day-to-day clinical practice via the internet, CareNet, Inc. provides pharmaceutical companies with solutions for effectively carrying out activities for disseminating pharmaceuticals information.
SanBio Co., Ltd.（TSE4592）
SanBio Co., Ltd. develops, manufactures, and sells regenerative cell drugs for treating central nervous system injuries or diseases such as stroke or traumatic brain injury. Currently the company is aiming to realize breakthrough therapeutic drugs for treating chronic- phase stroke and traumatic brain injury.
Modalis Therapeutics Corporation（Mothers 4883）
Possessing a powerful therapeutic drug creation platform based on the genome editing technology CRISPR, this bio-tech company aims to develop breakthrough therapeutic drugs for treating genetic diseases, which are said to number in excess of 6,000.
Practical development of gene therapeutic adipocyte medicines with therapeutic protein genes for the treatment of genetic enzyme and functional protein deficiencies.
Gene Therapy Research Institution Co., Ltd.
Developing world-leading innovative gene therapies with an innovative approach to the application of the highly safe adeno-associated virus (AAV) as a vector for carrying therapeutic genes. The focus is on intractable diseases such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease, etc…
evelopment of regenerative medicine for intervertebral disc tissue in the spinal column using other family members’ intervertebral disc medullary nucleus stem cells. Expected to be a cost-effective treatment method without major surgery. The company is seeking approval in the U.S. and Japan.
ILC Therapeutics Ltd
A Scotland-based biotech start-up company specializing in the regulation of the innate immune system. Working to develop novel first-in-class peptide therapies for the treatment of a variety of diseases including cancer, atopic dermatitis, psoriasis, allergic asthma and more!
Blueberry Therapeutics Limited
Conducts research and development specializing in the field of dermatology using groundbreaking “nanoformulation” technology.The proprietary technology can efficiently deliver drugs to tissues such as skin and nails that were previously difficult for drugs to reach and is currently developing marketable “best-in-class” drugs with enhanced safety and efficacy.
Commercialization of seed technology from Keio University. The lead product is a cardiomyocyte derived from other family’s iPS cells called “cardiomyocyte,” which produces ventricular muscle, important for the pump function of the heart, in high purity and increases the viability rate. Phase-II on going.